Objectives To update the EULAR points to consider (PtCs) on the use of immunomodulatory
therapies in COVID-19. Methods According to the EULAR standardised operating …

Objectives Severe systemic inflammation associated with some stages of COVID-19 and in
fatal cases led therapeutic agents developed or used frequently in Rheumatology being at …

Objective To summarise the available information on efficacy and safety of
immunomodulatory agents in SARS-CoV-2 infection. Methods As part of a European …

Objective To update the EULAR 2020 systematic literature review (SLR) on efficacy and
safety of immunomodulatory agents in SARS-CoV-2 infection. Methods As part of a EULAR …

Introduction: While waiting for the development of specific antiviral therapies and vaccines to
effectively neutralize the SARS-CoV2, a relevant therapeutic strategy is to counteract the …

Several immunosuppressive therapies have been investigated as potential treatments for
patients with severe and critical coronavirus disease 2019 (COVID-19). Notable examples …

The COVID-19 pandemic has resulted in more than 2 million deaths globally. Two
interconnected stages of disease are generally recognised; an initial viral stage and a …

In ARD, Ramiro et al report a number of sophisticated primary and sensitivity analyses from
an observational cohort study conducted in the Netherlands during the height of the COVID …

Background Immunomodulatory therapy has been extensively studied in randomized
clinical trials for the treatment of patients hospitalized for COVID-19 with inconsistent …

Diseases includes the freshly minted European Alliance of Associations for Rheumatology
(EULAR) points to consider on the pathophysiology and use of immunomodulatory therapies …